Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730477 | 0.83 | ITGB3 (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL4233928 | 0.76 | CACNA1B (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL192185 | 0.76 | CACNA1B (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL376117 | 0.76 | CACNA1B (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL30089915 | 0.75 | CACNA1B (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL6842296 | 0.75 | CACNA1B (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL14066376 | 0.74 | CACNA1B (0.44) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL1324835 | 0.74 | FOLH1 (0.56) | CTSKCTSS | |
| SCHEMBL2769978 | 0.74 | FOLH1 (0.56) | CTSKCTSS | |
| SCHEMBL1318658 | 0.74 | FOLH1 (0.56) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2013-08-29 | — | — | US | disclosed |
| US-8440653-B2 | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists | MIMETICA PTY LTD (AU) | 2013-05-14 | — | — | US | disclosed |
| US-8377925-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2013-02-19 | — | — | US | disclosed |
| US-20110059952-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2011-03-10 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CTSK 2694/4885CTSS 3094/4885HDAC4 1651/4885 |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CTSK 2694/4885CTSS 3094/4885HDAC4 1651/4885 |
| US-20110059952-A1 | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | CTSK 3148/4885CTSS 3918/4885HDAC4 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.